Navigation

Researchers at UCD

researcher

Orina Belton

Senior Lecturer

School Of Biomolecular & Biomed Science
Conway Institute
Belfield
Dublin 4

Tel: +353 1 7166748
Email: orina.belton@ucd.ie

Biography

Appointments

2014-present:Senior Lecturer (Pharmacology), School of Biomolecular and Biomedical Science, UCD
 
2007-2013:Lecturer (Pharmacology), School of Biomedical and Biomolecular Science, UCD

2004-2007:  Principal Investigator, SMMS, UCD

2003-2004:  Research Manager/Research Fellow, RCSI, Dublin

2001-2003:  Locum Lecturer, Clinical Pharmacology, RCSI, Dublin

1999-2003   Postdoctoral Research Fellow, RCSI, Dublin

1995-1999:     Postgraduate student, Department of Clinical Pharmacology, RCSI, Dublin

1994-1995: Research Assistant, Cell and Molecular Biology Group, NUIG, Galway

 

Professional

Honours and Awards

Year: 2011.
Title: SMMS Teacher of the Year Award
Year: 2010.
Title: Short Term Travel Fellowship
Year: 2007.
Title: HRB Translational Programme Grant
Year: 2006.
Title: SFI Principal Investigator Career Advancement
Year: 2005.
Title: HRB Project Grant
Year: 2005.
Title: EI Proof of Concept
Year: 2003.
Title: HRB Project Grant
Year: 2001.
Title: HRB Project Grant
Year: 2009.
Title: Development of in vivo imaging: facilitating translational research at UCD

Associations

Association: American Heart Association, Function/Role: Professional Member
Association: Council on Council on Atherosclerosis, Thrombosis and Vascular Biology (ATVB), Function/Role: Member
Association: European Atherosclerosis Society (EAS), Function/Role: Member
Association: International Atherosclerosis Society (IAS), Function/Role: Member

Patents

Patent WO 2009/127398 : CONJUGATED LINOLEIC ACID DERIVATIVES
         

Education

Year 1999 Institution: University College Dublin
Qualification: PhD Subject:
Year 1994 Institution: NUI Galway, IRL
Qualification: BSc Subject:
         

Publications

 

Book Chapters

Maguire PB, Belton O, O'Donoghue N & Coppinger JC. ; (2006) 'Platelet-endothelial interactions' In: Aird, W.C (eds). The Endothelium: A Comprehensive Reference. Cambridge, UK: Cambridge Univerity Press. [Details]
McClelland S, Cox C, O¿Connor R, Fitzgerald D, Belton O; (2009) 'Identification of novel anti-atherosclerotic effects of conjugated linoleic acid in vascular cells' In: Asher Kimchi (eds). Current Advances in Heart Disease. Canada: International Proceedings Division. [Details]
Belton O, McClelland S, Fitzgerald D; (2008) 'Cycloxygenase inhibition in atherothrombotic disease' In: Dominick J. Angiolillo, Adnan Kastrati, Daniel Simon (eds). A Clinical Guide to the use of Antithrombotic Drugs in Coronary Artery Disease. London: Informa Healthcare. [Details]
McClelland S, Cox C, O¿Connor R, Fitzgerald D, Belton O; (2009) 'Identification of novel anti-atherosclerotic effects of conjugated linoleic acid in vascular cells' In: Asher Kimchi (eds). Current Advances in Heart Disease. Canada: International Proceedings Division. [Details]
Belton O, Forde R, Lorez HP, Fitzgerald DJ. ; (1998) 'Cyclooxygenase expression in a rat model of focal cerebral ischemia' In: Belton O, Forde R, Lorez HP, Fitzgerald DJ. ; (eds). Essential Fatty Acids and Eicosanoids. *: AOCS Press. , pp.61-63 [Details]
 

Peer Reviewed Journals

Duffy, MM,Pindjakova, J,Hanley, SA,McCarthy, C,Weidhofer, GA,Sweeney, EM,English, K,Shaw, G,Murphy, JM,Barry, FP,Mahon, BP,Belton, O,Ceredig, R,Griffin, MD (2011) 'Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor'. European Journal of Immunology, 41 :2840-2851. [DOI] [Details]
McCarthy C, Duffy MM, Mooney D, James WG, Griffin MD, Fitzgerald DJ, Belton O. (2012) 'IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis'. FASEB Journal, [Epub ahead of print] . [Details]
McCarthy C, Duffy MM, Mooney D, James WG, Griffin MD, Fitzgerald DJ, Belton O (2013) 'IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis'. FASEB Journal, 27 (2):499-510. [DOI] [Details]
McCarthy, C,Duffy, MM,Mooney, D,James, WG,Griffin, MD,Fitzgerald, DJ,Belton, O (2013) 'IL-10 mediates the immunoregulatory response in conjugated linoleic acid-induced regression of atherosclerosis'. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 27 :499-510. [DOI] [Details]
Reynolds, CM,Toomey, S,McBride, R,McMonagle, J,Morine, MJ,Belton, O,Moloney, AP,Roche, HM (2013) 'Divergent effects of a CLA-enriched beef diet on metabolic health in ApoE(-/-) and ob/ob mice'. J Nutr Biochem, 24 :401-411. [DOI] [Details]
McCarthy C, Lieggi NT, Barry D, Mooney D, de Gaetano M, James WG, McClelland S, Barry MC, Escoubet-Lozach L, Li AC, Glass CK, Fitzgerald DJ, Belton O (2013) 'Macrophage PPAR gamma Co-activator-1 alpha participates in repressing foam cell formation and atherosclerosis in response to conjugated linoleic acid'. EMBO molecular medicine, 5 (9):1443-1457. [DOI] [Details]
Belton, O.,Byrne, D.,Kearney, D.,Leahy, A.,Fitzgerald, D. J.; (2000) 'Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis'. Circulation, 102 (8):840-5. [Details]
Murphy, J. F.,Steele, C.,Belton, O.,Fitzgerald, D. J.; (2003) 'Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphavbeta3'. Br J Haematol, 121 (1):157-64. [Details]
Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ, Emili A, Fitzgerald DJ & Maguire PB; (2004) 'Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions'. Blood, 103 :2096-2104. [Details]
Toomey, S,Harhen, B,Roche, HM,Fitzgerald, D,Belton, O; (2006) 'Profound resolution of early atherosclerosis with conjugated linoleic acid'. Atherosclerosis, 187 :40-49. [DOI] [Details]
McClelland, S,Gawaz, M,Kennerknecht, E,Konrad, CSI,Sauer, S,Schuerzinger, K,Massberg, S,Fitzgerald, DJ,Belton, O; (2009) 'Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse'. Atherosclerosis, 202 (NA):84-91. [DOI] [Details]
McClelland, S,Cox, C,O'Connor, R,de Gaetano, M,McCarthy, C,Cryan, L,Fitzgerald, D,Belton, O; (2010) 'Conjugated linoleic acid suppresses the migratory and inflammatory phenotype of the monocyte/macrophage cell'. Atherosclerosis, 211 :96-102. [DOI] [Details]
McCarthy, C,O'Gaora, P,James, WG,McClelland, S,Fitzgerald, DJ,Belton, O,de Gaetano, M; (2010) 'SorLA modulates atheroprotective properties of CLA by regulating monocyte migration'. Atherosclerosis, 213 :400-407. [DOI] [Details]
Duffy MM, Pindjakova J, Hanley SA, McCarthy C, Weidhofer GA, Sweeney EM, English K, Shaw G, Murphy JM, Barry FP, Mahon BP, Belton O, Ceredig R, Griffin MD; (2011) 'Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor'. J IMMUNOL, 41 (10):2840-2851. [DOI] Link to full text [Details]
Mooney D, McCarthy C, Belton O (2012) 'Effects of conjugated linoleic acid isomers on monocyte, macrophage and foam cell phenotype in atherosclerosis'. Prostaglandins & other lipid mediators, 98 (3-4):56-62. [DOI] [Details]
Reynolds CM, Toomey S, McBride R, McMonagle J, Morine MJ, Belton O, Moloney AP, Roche HM (2012) 'Divergent effects of a CLA-enriched beef diet on metabolic health in ApoE(-/-) and ob/ob mice'. Journal of Nutritional Biochemistry, Epub ahead of print . [DOI] [Details]
McClelland, SE, Ballou, LR, Fitzgerald, DJ, Belton, OA, ; (2007) 'COX-2 gene deletion increases advanced aortic arch atherosclerosis in the ApoE-/- mouse model'. ARTERIOSCL THROM VAS, 27 :97-97. [Details]
McClelland, SE, OConnor, R, Buckmaster, PE, Fitzgerald, DJ, Belton, OA, ; (2007) 'Conjugated linoleic acid alters the pro-atherosclerotic phenotype of the monocyte/macrophage - Evidence for the involvement of a novel signalling pathway'. Atherosclerosis Supp, 8 :42-42. [Details]
Toomey S, Roche H, Fitzgerald D, Belton O.; (2003) 'Regression of pre-established atherosclerosis in the apoE-/- mouse by conjugated linoleic acid'. Biochemical Society Transactions, 31 (5):1075-1079. [Details]
Pidgeon GP, Tamosiuniene R, Chen G, Leonard I, Belton O, Bradford A, Fitzgerald DJ.; (2004) 'Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2'. Circulation, 110 (17):2701-2707. [Details]
Belton O, Duffy A, Toomey S, Fitzgerald DJ.; (2003) 'Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis'. Circulation, 108 (24):3017-3023. [Details]
Duffy T, Belton O, Bresnihan B, FitzGerald O, FitzGerald D; (2003) 'Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis'. Drugs, 63 (Suppl 1):31-36. [Details]
Belton O, Fitzgerald D.; (2003) 'Cyclooxygenase-2 inhibitors and atherosclerosis'. Journal of the American College of Cardiology, 41 (10):1820-1822. [Details]
Murphy JF, Steele C, Belton O, Fitzgerald DJ.; (2003) 'Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphavbeta3'. British Journal of Haematology, 121 (1):157-164. [Details]
Belton O, Fitzgerald DJ. ; (2003) 'Cyclooxygenase isoforms and atherosclerosis'. Expert Rev Mol Med, :1-18. [Details]
Connolly E, Bouchier-Hayes DJ, Kaye E, Leahy A, Fitzgerald D, Belton O; (2002) 'Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty'. Journal of Pharmacology and Experimental Therapeutics, 300 (2):393-398. [Details]
 

Conference Publications

McClelland SE, O'Connor R, Buckmaster P, Fitzgerald DJ, Belton O (2007) Conjugated linoleic acid alters the pro-atherosclerotic phenotype of the monocyte/macrophage - evidence for the involvement of a novel signalling pathway Atherosclerosis Supplements [Details]
Lieggi N, McClelland S, Fitzgerald DJ, Belton O (2008) Conjugated Linoleic Acid Inhibits Macrophage Foam Cell Formation Atherosclerosis Thrombosis Vascular Biology [Details]
Cox C, Guisot N Devocelle, Fitzgerald DJ, Belton O (2008) ATVB 2008 Nitrosylated Conjugated Linoleic Acid: A Novel Antiatherogenic and Antiplatelet Agent Atherosclerosis Thrombosis vascular Biology [Details]
McCarthy C, Cox C, Belton O (2009) Conjugated linoleic acid reduces expression of migratory regulator of Sorl1 in the vasculature Atherosclerosis Supplements [Details]
Mooney DM, barry D,Lieggi N, McCarthy C, Fitzgerald DJ, Belton O (2011) A potential atheroprotective role of PGC1α in monocytes and macrophage derived foam cells Atherosclerosis Thrombosis vascular Biology [Details]
McCarthy C, Fitzgerald DJ, Belton O, (2011) Modulation of Il-10 Signalling Pathway Is a Potential Mediator of Regression of Atherosclerosis Atherosclerosis Thrombosis Vascualr Biology [Details]
McCarthy C, Duffy M, Mooney D, James W, Fitzgerald DJ, Griffin MD, Belton O, (2012) Il-10 Regulates the Immunoregulatory Response in the Regression of Atherosclerosis Circulation Research [Details]
McCarthy C, Mooney D, de Gaetano M, James W, Fitzgerald DJ, Belton O (2012) Activation of the Nuclear Receptor Coactivator PGC-1{alpha} Mediates an Atheroprotective Effect Circulation Research [Details]
Belton O, McClelland S, Gawaz M, Kennerknecht E, Konrad CS, Sauer S, Schuerzinger K, Massberg S, Fitzgerald DJ, ; (2007) Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse Atherosclerosis Thrombosis Vascular Biology [DOI] [Details]
McCarthy C, Mooney D, Fitzgerald DJ, Belton O ; (2010) Identification of a PGC1a regulated network induced by conjugated linoleic acid in the regression of atherosclerosis Atherosclerosis Thrombosis and Vascular Biology [Details]
McClelland S, Ballou L, Fitzgerald D, Belton O; (2007) COX-2 gene deletion increases advanced aortic arch atherosclerosis in the apoE-/- mouse model Atherosclerosis Thrombosis and Vascular Biology [Details]
McCarthy C, James W, Fitzgerald DJ, Belton O ; (2010) Novel regulation and recognition of the role of SorLA in atherosclerotic vasculature Keystone Symposia Advances in Molecular Mechanisms in Atherosclerosis 2010 [Details]
McClelland S, Fitzgerald D, Belton O; (2007) Conjugated linoleic acid alters the pro-atherosclerotic phenotype of the monocyte/macrophage- evidence for the involvement of a novel signalling pathway European Atherosclerosis Society 76th Congress [Details]
McClelland S, Fitzgerald D, Langenbach R, Belton O; (2004) Cyclooxygenase-1 Gene Deletion Inhibits Atherosclerosis in the ApoE-/- Mouse Atherosclerosis Thrombosis and Vascular Biology [Details]
Toomey S, Dooley C, Sharkey C, Fitzgerald D, Belton O; (2004) The effect of a novel inhibitor of the peroxidase activity of cyclooxygenase-1 on the development of atherosclerosis Atherosclerosis Thrombosis and Vascular Biology [Details]
Toomey S, Roche H, Fitzgerald D, Belton O; (2003) Profound resolution of atherosclerotic lesions by the 9-cis, 11-trans isomer of conjugated linoleic acid Atherosclerosis Thrombosis and Vascular Biology [Details]
Duffy A, Fitzgerald D, Belton O; (2001) Inhibition of cyclooxygenase isoforms and the development of atherosclerosis Circulation (American Heart Association) [Details]
Connolly E, Leahy A, Fitzgerald D, Belton O; (2000) Effect of selective Cyclooxygenase-1 and '2 inhibition on intimal hyperplasia in a rat model of balloon angioplasty Circulation (American Heart Association) [Details]
                       

Abstract

Toomey SM, Dooley CM, Sharkey CT, Roche HM, Fitzgerald DJ, and Belton OA.; (2003) Profound resolution of atherosclerotic lesions by the 9-cis, 11-trans isomer of Conjugated Linoleic Acid. Abstract [Details]
Toomey SM, Sharkey CT, Dooley CM, Fitzgerald DJ, and Belton OA.; (2004) The effect of a novel inhibitor of the peroxidase activity of cyclooxygenase-1 on the development of atherosclerosis. Abstract [Details]
McCarthy, C,Cox, C,Belton, O (2009) CONJUGATED LINOLEIC ACID REDUCES EXPRESSION OF MIGRATORY REGULATOR SORL1 IN THE VASCULATURE. Abstract [Details]
McCarthy, C,Duffy, M,Mooney, D,James, W,Fitzgerald, DJ,Griffin, MD,Belton, O (2012) Il-10 Regulates the Immunoregulatory Response in the Regression of Atherosclerosis. Abstract [Details]
McCarthy, C,Mooney, D,de Gaetano, M,James, W,Fitzgerald, DJ,Belton, O (2012) Activation of the Nuclear Receptor Coactivator PGC-1 alpha Mediates an Atheroprotective Effect. Abstract [Details]
       

Reviews

Mooney, D,McCarthy, C,Belton, O (2012) Effects of conjugated linoleic acid isomers on monocyte, macrophage and foam cell phenotype in atherosclerosis. Reviews [DOI] [Details]
                                                     

Research

Research Interests

Atherosclerosis, the primary cause of heart disease and stroke is a complex progressive disease with multiple genetic and environmental contributions. To date there have been no defined pathways which would explain how atherosclerosis could be reversed or indeed if such a pathway exists. The implications of this are important since most patients present with pre-established lesions and the therapeutic goal would be to reverse the lesion by discriminating the pathways for regression.

 

Our current programme of research investigates the fundamental mechanisms governing atherosclerosis regression. Our laboratory has established a novel model of atherosclerosis regression in vivo, achieved by administration of conjugated linoleic acid (CLA) apoE knockout mouse model of atherosclerosis. In addition, we have established Intravital Microscopy (IVM) as core facility in UCD. This system is employed to collect functional information about dynamic processes occurring in tissues and organ systems that are maintained in their natural state. For example, we have shown using this technology that CLA inhibits monocyte recruitment, monocyte-endothelial cell adhesion and trans-endothelial migration in the carotid and femoral arteries; providing novel in vivo insights into the molecular mechanisms mediated by CLA.

 

Our recent research has focused on the identification of distinct genes/pathways regulated by CLA that may yield further information as to how atherosclerosis can be reversed. To do this we employ an approach that involves confirmation of a phenotypic change in vivo by en face analysis and intravital microscopy. Using a transcriptomic and proteomic approach we then construct networks associated with the altered phenotype, followed by identification of central or ¿hub¿ genes which regulate the network. Using cellular models and functional assays we validate a functional role for these hub genes in vitro examining the effect of gene deletion or over expression on, monocyte-endothelial interactions, integrin regulation, adhesion, migration and foam cell formation. We then extend this study into human patients to seek evidence for regulation of the target/ ¿hub¿ genes in atherosclerotic disease progression.

Through this approach we have identified novel pathways. Some have complimentarity with pathways associated with atherosclerosis susceptibility for example we have recently characterized and ascribed a functional role for one target gene, SorLA in monocyte migration and have confirmed its regulation in human disease. In addition we have identified a PGC-1α regulated pathway associated with inhibition of monocyte migration and foam cell formation..  Our hypothesis is that this pathway can be further exploited to identify the key components involved in regression of atherosclerosis. Importantly, our data shows that the monocyte/macrophage cell is the cellular target through which CLA mediates its atheroprotective effect and suggests that alteration of monocyte/macrophage function is an important strategy in novel treatments for atherosclerosis.

 

Our work has a strong translational component and our current research is to determine if the novel targets, identified by us, they are modifiable in human disease. To this end, we have shown that macrophage specific deletion of PGC-1alpha promoted foam cell formation and accelerated atherosclerosis in vivo, suggesting that targeted manipulation of this network may retard the development of human disease. Importantly, our data indicates that PGC-1α is expressed in the macrophage/foam cells of atherosclerotic plaques from both symptomatic and asymptomatic patients where its expression is inversely associated with disease progression. The importance of this is that it has facilitated the identification of novel ¿druggable¿ targets for more effective therapies, which can now be achieved through our collaboration with Industry.

FUNDING AGENCIES:
SFI
EI
HRB

Research Projects

Sponsor : University College Dublin (UCD)
Title : Development of in vivo imaging: facilitating translational research at UCD
Start Date / End Date : 01-FEB-10 / 31-JAN-11
Sponsor : Enterprise Ireland (EI)
Title : Functional Food Centre (WP6)
Start Date / End Date : 01-JUN-08 / 31-MAY-13
Sponsor : Health Research Board (HRB)
Title : ICEAGE: Investigation of CLA and its effect on atheroschlerosis gene expression
Start Date / End Date : 01-FEB-08 / 31-JAN-13
Sponsor : Health Research Board (HRB)
Title : The anti-atherogenic activity of CLA isomers
Start Date / End Date : 01-OCT-05 / 30-SEP-08
Sponsor : Enterprise Ireland (EI)
Title : Nitrosylated conjugated linoleic acids: novel treatments for existing atherosclerosis
Start Date / End Date : 01-SEP-05 / 31-AUG-06
Sponsor : Health Research Board (HRB)
Title : Cyclooxygenases in Atherosclerosis: Exploring the Cardiovascular Risk of COX-2 Inhibitors
Start Date / End Date : 01-JUL-04 / 30-JUN-07
Sponsor : Science Foundation Ireland (SFI)
Title : The genetics controlling the risk of Atherosclerosis
Start Date / End Date : 01-SEP-06 / 31-DEC-09
Sponsor : Cancer Research Ireland (CRI)
Title : Regulation of tumour-stromal interaction by cyclooxygenase-2 in gastrointestinal cancers
Start Date / End Date : 01-OCT-05 / 30-SEP-08
   

Teaching

Teaching Philosophy

To create an environment of mutual respect and to encourage, support and inspire students reach mutual goals by creatively exploring the subject in new ways. To develop and enhance student¿s self-belief so that they become empowered to explore and ask questions.
 

Enhancement of Teaching

Review and Enhancement of Curriculum

During 2010-2012 I was the academic representative for Pharmacology on the SBBS Committee appointed for restructuring Stage 2 Science Programme. This involved a complete review of the current curriculum and the development and design of new practical and lecture modules as well as assessment strategies. A major outcome has been the introduction of two core practical modules where students learn basic research, experimental and computational skills. These are developed throughout the module, in parallel with the student¿s knowledge, competence and ability, to more advanced and applied techniques. In addition, I have been the leader on the design, content and assessment strategies for a new Stage 2 Module ¿Principles of Pharmacology¿ (PHAR20040) which forms part of the core curriculum for the B.Sc. degree in Pharmacology. This module covers the fundamental principles of interactions of the body with drugs, pharmacology of the autonomic nervous system and therapeutic modulation of cardiovascular function. This module is designed to incorporate self-directed and independent learning. Through the use of video developed and designed by me, it integrates practical applications of a particular topic thus providing the students with a connection between How we do Science and How we teach Science. As module coordinator I have been involved in changing the strategy for delivering and assessing the Cardiovascular and Renal Disease module (PHAR30110) for Stage 3 Medicine. I developed the module structure to ensure that students are familiar with the pathology of the disease before exploring the pharmacological strategies. This has been achieved with support from my colleagues in Pathology and Clinicians who contribute to the module. As Module coordinator on Stage 4 Advanced Cardiovascular Pharmacology I designed and developed the module to focus on research informed current developments and applications of cardiovascular pharmacology in the clinical, pharmaceutical and industry arenas.

Developing as a Teacher

Innovation & Leadership

Leader in a new initiative with 5 other Irish Universities to work with an educational publisher of online courses based at Imperial College London to design a curriculum of high quality online courses for early to mid-career researchers. Responsibility for the review, development, design and delivery of all cardiovascular pharmacology content in lectures, tutorials and practicals in Stage 2, Stage 3 and Stage 4. Member of the International team to promote and recruit students UCD Pre-Masters programmes (2010/2011).

Collaborators

Internal Collaborators

Research Team

Dr. Denis Barry, Post Doctoral Research Fellow

Dr. Cathal McCarthy, Post Doctoral Research Fellow
 
Dr. Eugene Demosey, Post Doctoral Research Fellow 

Ms. Monica de Gaetano, PhD Student

Mr. Declan Mooney, PhD Student

Ms. Karen Haughton, PhD Student

Mr. Will James, Research Scientist

External Collaborators

Prof Aldons Jake Lusis,
Dept. Human Genetics, UCLA, CA, USA

Prof. Chrostopher Glass,
UCSD, USA 

Ms. Mary Barry,
Consultant Vascular Surgeon, SVUH, Diblin

Prof. Matthew Griffin,
Professor of Transplant Medicine, NUIG, Galway 
 
Prof. Paola Patrignani,
University of Chietit, italy